Swiss expansion for Ferring

- Last updated on GMT

Related tags: Medicine

Ferring Pharmaceuticals has unveiled plans to invest €90 million in
a state-of-the-art production site in Saint-Prex in Switzerland.

Denmark's Ferring Pharmaceuticals has unveiled plans to build state-of-the-art production site in Saint-Prex in Switzerland. The company will invest nearly €90 million in the site construction and expects to employ approximately 250 people at the site by 2008.

Ferring has made Switzerland the core of its group, establishing its headquarters in Lausanne in 2000.

"The new production site will allow us to meet a growing demand for our current products and secure the future supply of innovative new medicines that we have in development for our patients around the world,"​ commented Frederik Paulsen, the son of Ferring's late founder of the same name.

Building work on the facility is scheduled to start this autumn, with completion tipped for spring 2005 and commercial production planned for 2007. The completed unit will cover 23,000 square metres, including production, packaging and administration.

Ferring Pharmaceuticals was one of the first companies in the world to produce synthetic peptides on a commercial scale, and has developed a range of products in urology, gastroenterology, fertility and obstetrics with annual sales of more than €500 million.

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Flow Cytometry Services

Flow Cytometry Services

Q² Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

Follow us


View more